Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celgene Corp (CELG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 81,960,008
  • Shares Outstanding, K 787,320
  • Annual Sales, $ 11,229 M
  • Annual Income, $ 1,999 M
  • 36-Month Beta 1.79
  • Price/Sales 7.25
  • Price/Cash Flow 17.16
  • Price/Book 8.26

Price Performance

See More
Period Period Low Period High Performance
1-Month
94.55 +10.10%
on 10/26/17
139.40 -25.32%
on 10/18/17
-34.76 (-25.03%)
since 10/17/17
3-Month
94.55 +10.10%
on 10/26/17
147.17 -29.27%
on 10/02/17
-23.48 (-18.40%)
since 08/17/17
52-Week
94.55 +10.10%
on 10/26/17
147.17 -29.27%
on 10/02/17
-17.98 (-14.73%)
since 11/17/16

Most Recent Stories

More News
Cancer Space Update: Label Expansion for Three Major Drugs

This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

AVEO : 3.11 (+1.63%)
CELG : 104.10 (+0.73%)
AZN : 33.46 (-0.18%)
BLUE : 163.20 (+1.90%)
MRK : 55.20 (+0.05%)
RHHBY : 29.1000 (+0.71%)
PFE : 35.37 (-0.53%)
Celgene CAR-T Therapy Gets Breakthrough Therapy Designation

FDA grants Breakthrough Therapy Designation to Celgene's (CELG) chimeric antigen receptor T-cell (CAR-T) therapy candidate, bb2121.

CELG : 104.10 (+0.73%)
BLUE : 163.20 (+1.90%)
NVS : 83.98 (+1.16%)
GILD : 72.44 (+0.04%)
Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3

After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.

CELG : 104.10 (+0.73%)
VRTX : 147.41 (-0.36%)
ABBV : 93.61 (-0.91%)
GILD : 72.44 (+0.04%)
AMGN : 170.00 (-0.45%)
ALXN : 110.87 (+0.49%)
BIIB : 313.97 (unch)
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma

Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced that bb2121, a chimeric antigen receptor T-cell (CAR-T) therapy targeting b-cell maturation antigen...

CELG : 104.10 (+0.73%)
BLUE : 163.20 (+1.90%)
CELGZ : 1.10 (+2.80%)
How to Survive a Biotech Blowup

This post How to Survive a Biotech Blowup appeared first on Daily Reckoning . Big biotech stocks were primed and ready to rip higher at the beginning of the fourth quarter. But, the market threw a...

CELG : 104.10 (+0.73%)
IBB : 311.21 (+0.13%)
GILD : 72.44 (+0.04%)
REGN : 391.59 (-0.79%)
AMGN : 170.00 (-0.45%)
XBI : 81.43 (unch)
The Zacks Analyst Blog Highlights: Facebook, Celgene, BlackRock, Danaher and BP

The Zacks Analyst Blog Highlights: Facebook, Celgene, BlackRock, Danaher and BP

BLK : 473.99 (-0.01%)
CELG : 104.10 (+0.73%)
FB : 179.00 (-0.33%)
BP : 39.09 (+0.83%)
DHR : 93.30 (-0.30%)
Top Stock Reports for Facebook, Celgene & BlackRock

Top Stock Reports for Facebook, Celgene & BlackRock

BLK : 473.99 (-0.01%)
CELG : 104.10 (+0.73%)
FB : 179.00 (-0.33%)
EOG : 101.64 (+0.21%)
BP : 39.09 (+0.83%)
DHR : 93.30 (-0.30%)
Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised

Corcept Therapeutics' (CORT) earnings miss but sales beat expectations in the third quarter of 2017. The company remains focused on advancing its cortisol modulation platform.

AGEN : 3.70 (-0.27%)
CORT : 18.39 (-3.46%)
CELG : 104.10 (+0.73%)
LGND : 140.31 (-0.99%)
Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y

Agios (AGIO) reports narrower-than-expected loss with revenues marginally beating estimates. The top line also improves year over year, thanks to reimbursement received from Celgene.

AGIO : 59.64 (+0.02%)
CELG : 104.10 (+0.73%)
LGND : 140.31 (-0.99%)
EXEL : 26.38 (+2.13%)
Biotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All Fronts

It was all about earnings this week with major biotech companies like Gilead (GILD), Celgene and Amgen reporting third quarter results.

CELG : 104.10 (+0.73%)
VYGR : 12.95 (-4.07%)
VRTX : 147.41 (-0.36%)
GWPH : 115.88 (-1.42%)
INCY : 105.47 (-0.95%)
ABBV : 93.61 (-0.91%)
AMGN : 170.00 (-0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

See More

Key Turning Points

2nd Resistance Point 105.33
1st Resistance Point 104.71
Last Price 104.10
1st Support Level 103.36
2nd Support Level 102.63

See More

52-Week High 147.17
Fibonacci 61.8% 127.07
Fibonacci 50% 120.86
Fibonacci 38.2% 114.65
Last Price 104.10
52-Week Low 94.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart